# Small for Gestational Age Preterm Neonates Exhibit Defective GH/IGF1 Signaling Pathway

Emmanuelle Motte-Signoret, Shivani Shankar-Aguilera, Sylvie Brailly-Tabard, Yohan Soreze, Valentina Dell Orto, Rafik Ben Ammar, Daniele de Luca, Pascal Boileau

► To cite this version:

Emmanuelle Motte-Signoret, Shivani Shankar-Aguilera, Sylvie Brailly-Tabard, Yohan Soreze, Valentina Dell Orto, et al.. Small for Gestational Age Preterm Neonates Exhibit Defective GH/IGF1 Signaling Pathway. Frontiers in Pediatrics, 2021, 9, 10.3389/fped.2021.711400. hal-03332020

HAL Id: hal-03332020

https://hal.inrae.fr/hal-03332020

Submitted on 31 May 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for
updates

# Small for Gestational Age Preterm Neonates Exhibit Defective GH/IGF1 Signaling Pathway

Emmanuelle Motte-Signoret<fnref n="1" />,<fnref n="2" />,³*, Shivani Shankar-Aguilera<fnref n="1" />, Sylvie Brailly-Tabard⁴, Yohan Soreze<fnref n="1" />, Valentina Dell Orto<fnref n="1" />, Rafik Ben Ammar<fnref n="1" />, Daniele De Luca<fnref n="1" /> and Pascal Boileau<fnref n="2" />,⁵

OPEN ACCESS

**Edited by:**

Lynette Kay Rogers,
The Research Institute at Nationwide
Children's Hospital, United States

**Reviewed by:**

Anna Kistner,
Karolinska University Hospital, Medical
Radiation Physics and Nuclear
Medicine, Sweden

Renata Stawerska,
Polish Mother's Memorial Hospital
Research Institute, Poland

*Correspondence:

Emmanuelle Motte-Signoret
emanuelle.mottesignoret
@ght-yvelinesnord.fr

**Specialty section:**

This article was submitted to
Neonatology,
a section of the journal
Frontiers in Pediatrics

Received: 18 May 2021

Accepted: 14 July 2021

Published: 10 August 2021

**Citation:**

Motte-Signoret E, Shankar-Aguilera S, Brailly-Tabard S, Soreze Y, Dell Orto V, Ben Ammar R, De Luca D and Boileau P (2021) Small for Gestational Age Preterm Neonates Exhibit Defective GH/IGF1 Signaling Pathway. *Front. Pediatr.* 9:711400.
doi: 10.3389/fped.2021.711400

**Objective:** To investigate the impact of fetal growth restriction (FGR) on hormonal regulation of post-natal growth and glucose metabolism [via insulin and growth hormone (GH)/Insulin-like Growth factor 1 (IGF1) axis pathways] in small for gestational age (SGA) neonates.

**Methods:** We conducted a monocentric observational prospective comparative study on 73 singleton babies born with a weight inferior to 2,000 g. We analyzed auxological (weight, height and head circumference), and hormonal (GH, IGF1, and insulin plasma concentrations) data comparing SGA and appropriate for gestational age (AGA) neonates, between day 1 and 60.

**Results:** One third (23/73) of the neonates were SGA. Twenty-five percent (18/73) required insulin for idiopathic hyperglycemia of prematurity and were smaller in weight and head circumference at discharge. In the SGA group compared with the AGA group, GH plasma concentrations were higher at day 3 (70.1 vs. 38.0 mIU/L) and IGF1 plasma concentrations were higher at day 10 (29.0 vs. 18.7 ng/ml).

**Conclusions:** SGA neonates displayed resistance to GH and IGF1, concomitant to insulin resistance. This could partially explain the initial defective catch-up growth and, later in life, the higher prevalence of metabolic syndrome in this population.

**Keywords:** small for gestational age, preterm infants, fetal growth restriction, post-natal growth, idiopathic hyperglycemia, hormone resistance, metabolic syndrome, fetal programming 3

INTRODUCTION

Preterm birth is a major risk factor of neonatal morbidity and mortality which is worsened with fetal growth restriction (FGR) (1-3). In the 90's, Barker's work revealed that small for gestational age (SGA) neonates, defined as a birthweight below the 10th percentile for the gestational age, had an increased risk to develop metabolic syndrome when adults. This was the beginning of the concepts of fetal programming and the thrifty phenotype hypothesis (4, 5). Long term alterations in energetic metabolism affect these children with some of them exhibiting early insulin resistance (6). In addition, idiopathic hyperglycemia is frequent among extremely preterm or very low birth

<footnote n="1">¹Assistance Publique-Hôpitaux de Paris, Béclere Hospital, GH Paris Sud, Neonatal Intensive Care Unit, Clamart, France,</footnote>

<footnote n="2">²Poissy St Germain Hospital, Neonatal Intensive Care Unit, Poissy, France, ³Paris-Saclay University, Université Versailles Saint Quentin, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, BREED, Jouy-en-Josas, France, ⁴Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Molecular genetics Pharmacogenetics and Hormonology, Le Kremlin-Bicêtre, France, ⁵Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin-Bicêtre, France</footnote>
weight (VLBW) neonates (7, 8), and is usually explained by defects in glucose regulation with insulin resistance and lower insulin secretion (9, 10).

During fetal life and the first months after birth, growth is predominantly depending on nutrient intake and fetal insulin (11). The growth hormone (GH)/Insulin-like Growth factor 1 (IGF1) axis has a minor role in the regulation of growth during the first months of life, but is essential for glucose homeostasis (12). Maternal and placental GH are not known to impact fetal growth either (13). It is likely that insulin and GH/IGF1 endocrine systems share some of their intracellular signaling pathways and have synergistic anabolic and metabolic actions during the first weeks of extra-uterine life. Recently, murine models have emphasized the correlation between lack of catch-up growth in SGA rats and GH resistance (14) and the existence of cross-linked interactions between insulin and GH/IGF1 axis pathways (15).

Prematurity compounded with FGR expose the neonate to an higher risk of perinatal mortality (16), postnatal growth failure and ultimately metabolic syndrome in adult life (17). We hypothesized that FGR alters GH/IGF1 post-natal signalization with mechanisms similar to insulin signalization defects, and could thus affects post-natal growth of SGA neonates. We conducted a prospective study in 73 low birth-weight (LBW) neonates, describing auxological evolution and hormonal assay during their hospitalization in neonatal intensive care unit (NICU) in order to address our hypothesis.

# METHODS

## Patients

This non-interventional comparative prospective cohort study was conducted in a single tertiary academic NICU between December 2015 and July 2016, with no modification of routine clinical care. It was approved by the local institutional review board (Paris Saclay University) and followed all the relevant local regulations (French Advisory Committee for the Protection of People, and CNIL n°2051804). Consent has been obtained from each patient's parent after full explanation of the purpose and nature of all procedures used.

All singleton, inborn neonates with birth weight < 2,000 g admitted to the NICU were eligible for inclusion. Gestational age was determined by ultrasound assessment during the first trimester of pregnancy. Exclusion criteria were multiple pregnancies, uncertain gestational age at birth, maternal diabetes, maternal height lower than 150 cm, established chromosomal abnormality, genetic disease or skeletal dysplasia.

Patient management was standardized according to the ESPGHAN guidelines for enteral and parenteral nutrition (18). Glucose intakes were initially 6 to 8 g/kg/d, advanced by 1 to 2 g/kg/d and the goal was to reach 12–15 g/kg/d

at the end of the first week. Glycaemia was measured on blood drops obtained by heel prick, and using point-of-care glucometer at the bedside. The administration of insulin for idiopathic neonatal hyperglycemia was initiated after three capillary glycaemia over 12 mmol/l, and introduced with intravenous continuous lispro insulin (initial posology 0.02 IU/kg/h secondarily adapted to capillary glycaemia sampled every 3 h).

## Data Collection

We collected clinical data [sex, gestational age, antenatal corticosteroids, etiology of prematurity, mode of delivery, insulin treatment, weight, height and head circumference (HC) at birth, around day 10, day 30 and day 60], in real time during hospitalization until discharge. Small and appropriate for gestational age (SGA and AGA) neonates were differentiated according to Fenton 2013 growth charts (19) taking for threshold the 10th percentile for weight and/or height. We defined extra-uterine growth retardation (EUGR) as growth values ≤10th percentile of intrauterine growth expectation based on estimated postmenstrual age in premature neonates at the time they are discharged from the hospital (20).

Plasma concentrations of IGF1, GH and insulin were measured between day 2 and 3, between day 8 and 10, and between day 25 and 35 using Sandwich immunometric assays (Immulite 2,000 XPi, Siemens Healthcare Diagnostics Erlangen, Germany for GH (detection thresholds: 3–1,000 mUI/L) and IGF1 (detection thresholds: 2–1,000 ng/mL) and Liaison, DiaSorin, Saluggia, Italy for Insulin, which does not crossmatch with lispro (detection thresholds: 0.87–500 µIU/mL)]. Blood was drawn through indwelling central venous lines or when not the case, by venipuncture at the same time of blood sampling for routine clinical care of the neonate. In case of venipuncture, non-pharmacological sedation (nursing 30% glucose solution) was given orally according to our clinical protocol, classically used in NICU without significantly modifying glycaemia.

We defined insulin resistance as the need for insulin treatment despite appropriate glucose intakes, and GH resistance as the association of elevated GH levels and extremely decreased IGF1 levels (below assay threshold).

## Statistical Analysis

Gaussian distributed data were expressed as mean +/- standard deviation. Differences in categorical variables were assessed by Chi2 or Fisher test, as appropriate. Continuous data were compared with Student test, correlation was tested with Pearson's coefficient.

We compared AGA vs. SGA groups, and patients requiring insulin therapy vs. the others (insulin and no insulin groups, respectively). The analysis was carried out with the statistical software GraphPad Prism 8.1. P-values < 0.05 were considered statistically significant.

<footnote>**Abbreviations:** FGR, fetal growth restriction; SGA, small for gestational age; AGA, appropriate for gestational age; GH, growth hormone; IGF1, insulin-like growth factor 1; IGF2, insulin-like growth factor 2; IU, international unit; NICU, neonatal intensive care unit; EUGR, extra-uterine growth retardation; HC, head circumference; VLBW, very low birth-weight; LBW, low birth-weight; SRS, silver-russel syndrome; HOMA, homeostasis model assessment of insulin resistance.</footnote>
# RESULTS

## Clinical Characteristics of the Study Population

Seventy-three LBW neonates were included in our study, 22 (30%) were born before 28 weeks GA, 23 (32%) were SGA. **Figure 1** describes the longitudinal evolution of the cohort: 60 babies (82%) were still hospitalized in our unit at day 10 (18 SGA), 39 (53%) at day 30 and only 17 (23%) at day 60. All SGA neonates had been discharged before day 60. Hormonal assays were performed in 51, 34, and 25 patients at day 3, 10, and 30, respectively.

Prematurity was medically induced in 49% (36/73) of all, and in 91% (21/23) of SGA neonates. Before 28 weeks of gestation, there was no preterm birth medically induced for fetal growth restriction (FGR). Conversely, preterm labor and preterm premature rupture of membranes rates were lower with a higher gestational age. Preterm birth was medically induced for FGR in 62% (14/23) of SGA neonates, whereas prematurity was spontaneous in 70% (35/50) of AGA neonates. Within the overall population, 26 neonates (36%) were extremely low birth weight (ELBW, <1,000 g), 22 (30%) and 55 (75%) were born before 28 and 32 weeks of gestation, respectively.

Birth auxological characteristics are described in **Table 1**. SGA neonates had a higher gestational age with a similar BW in comparison to AGA neonates. By definition, BW, BH and BHC in percentiles were significantly lower in SGA group. No difference was observed between the two groups for antenatal steroids. Eighteen (25%) neonates required insulin administration during their hospitalization, with a mean gestational age of 27.1 weeks and a mean BW of 881 g. Extremely preterm (<28 weeks) and ELBW infants had a significantly increased need for insulin treatment compared to the global study population (p = 0.0005 and p < 0.0001, respectively). There was no significant difference between AGA and SGA groups for need for insulin.

## Post-natal Growth

Thirty eight percent (15/39) of the babies exhibited EUGR at day 30 (8 within 32 AGA neonates (25%) vs. 100% of SGA neonates – *p* < 0.0001). Seventy one percent (12/17) of them had EUGR at day 60 and among them 90% were those who required insulin in the first days of life.

The post-natal growth of the whole population and according to SGA/AGA and insulin/no insulin requirement status is illustrated in **Figure 2**. Weight and height in percentile of SGA neonates persisted to be significantly lower than the AGA neonates at birth, day 10 and day 30, while the HC was not significantly different between the two groups at day. Weight and HC of neonates requiring insulin were not significantly different than those without insulin at birth but were significantly lower at day 60.

## Hormonal Regulation

GH, IGF1 and insulin plasma concentrations are shown in **Table 2** and **Supplementary Figure 1**. Fifty-one neonates had available measurements at day 3, 34 at day 10, and 25 at day 30 (respectively, 70, 47, and 34% of initial study population). We

compared the results between AGA vs. SGA infants and between those who required insulin treatment vs. the others.

GH plasma concentrations during the first month of life exhibited a mean range of 50, 38, and 47 mIU/l at day 3, day 10 and day 30 respectively. Forty two neonates (82%) exhibited GH levels to 20 mIU/L at day 3, 31 (91%) at day 10 and 23 (92%) at day 30. On the contrary, 4 (8%) neonates exhibited GH levels lower to 10 mIU/ml at day 3, 1 (3%) at day 10 and none at day 30. GH plasma concentrations were higher at day 3 in SGA (70.1 vs. 38.0 mIU/L; *p* = 0.004). We found no correlation between GH at birth and GA nor BW and a low correlation between GH and BW Fenton percentile (R² = 0.09, *p* = 0.03).

IGF1 plasma concentrations exhibited a mean range of 7 ng/ml at birth, progressively increased during the first month (20 ng/ml at day 10 and 25 ng/ml at day 30) and were below the minimum threshold of the assay in 13 neonates (25%) at day 3, 2 (6%) at day 10 and 1 (4%) at day 30, regardless of weight, gestational age and weight for gestational age. At birth, IGF1 levels discretely correlated to GA (R² = 0.08, *p* = 0.04) and BW (R² = 0.14, *p* = 0.007) but not BW Fenton percentile. IGF1 plasma concentrations were higher at day 10 in SGA compared to AGA neonates (29 vs. 19 ng/mL; *p* < 0.001).

There was no significant difference of GH and IGF1 plasma concentrations during the first month of life between neonates needing insulin therapy and the others. Mean insulin levels were 15.5 mIU/ml at day 3 and decreased to 11.0 and 11.5 mIU/ml at day 10 and day 30. Low insulin levels (< 5 mIU/ml) were observed in 13 (25%), 7 (21%) and 3 (12%) neonates whereas 10 (20%), 2 (6%) and 1 (4%) neonates exhibited high insulin levels (> 40 mIU/ml) at day 3, day 10 and day 30, respectively. There were no significant differences in insulin plasma concentrations between AGA and SGA neonates. However, we found significantly higher insulin levels in babies requiring insulin treatment at day 10. There was no correlation between insulin plasma concentrations with either gestational age or birth weight.

At day 3, we found no correlation between GH and IGF1 plasma concentrations, for any gestational age or weight. However, 2 SGA neonates exhibited extremely high plasma concentrations of GH (208 and 171 mIU/L) with concomitant concentrations of IGF1 below the minimum threshold of the assay (<1 ng/ml). At day 30, GH plasma concentrations were inversely correlated to IGF1 levels (R² = 0.38, *p* = 0.01) in AGA babies.

# DISCUSSION

Glucose metabolism ontogenesis and fetal and neonatal growth are mainly regulated by insulin and GH/IGF1 axis pathways (21, 22). Prematurity and fetal growth restriction expose the neonate to growth failure and metabolic syndrome in childhood and when adults (17, 23-25). We have found that post-natal growth was altered in babies who required insulin for idiopathic hyperglycemia of prematurity and that SGA neonates were likely resistant to GH and IGF1. These results support the existence of cross-linked interactions between insulin and GH/IGF1 axis
<figure><img src="image_3.png" /><figcaption>FIGURE 1 | Flow chart of the study.</figcaption></figure>

<table><caption>TABLE 1 | Main characteristics of the study population.</caption><thead><tr><th></th><th>All</th><th>&lt; 28 weeks GA</th><th>AGA</th><th>SGA</th></tr></thead><tbody><tr><td>N</td><td>73</td><td>22</td><td>50</td><td>23</td></tr><tr><td>GA (weeks)</td><td>29.8 ± 3.0</td><td>26.5 ± 1.2</td><td>28.6 ± 2.2</td><td>32.6 ± 2.5***</td></tr><tr><td>&lt; 28 wZeeks GA (%)</td><td>22 (30)</td><td>–</td><td>18 (36)</td><td>4 (17) ns</td></tr><tr><td>SGA (%)</td><td>23 (32)</td><td>4 (18)</td><td>–</td><td>–</td></tr><tr><td>BW (g)</td><td>1,153 ± 314</td><td>828 ± 156</td><td>1,118 ± 310</td><td>1,230 ± 315</td></tr><tr><td>BW (percentile)</td><td>33 ± 25</td><td>42 ± 21</td><td>45.6 ± 20.3</td><td>5.9 ± 4.6***</td></tr><tr><td>BH (cm)</td><td>37.0 ± 3.3</td><td>33.5 ± 2.0</td><td>36.6 ± 3.3</td><td>37.8 ± 3.2</td></tr><tr><td>BH (percentile)</td><td>34 ± 28</td><td>43 ± 20</td><td>47.5 ± 24</td><td>6.0 ± 6.3***</td></tr><tr><td>BHC (cm)</td><td>26.3 ± 3.6</td><td>23.5 ± 1.4</td><td>25.8 ± 2.6</td><td>27.2 ± 2.2*</td></tr><tr><td>BHC (percentile)</td><td>36 ± 27</td><td>40 ± 20</td><td>48.0 ± 24.5</td><td>10.4 ± 9.8***</td></tr><tr><td>Sex F/M</td><td>36/37</td><td>10/12</td><td>23/27</td><td>13/10</td></tr><tr><td>Antenatal steroids n (%)</td><td>57 (78)</td><td>18 (82)</td><td>39 (78)</td><td>18 (78) ns</td></tr><tr><td>Insulin therapy n (%)</td><td>18 (25)</td><td>12 (55)</td><td>15 (30)</td><td>3 (13) ns</td></tr></tbody></table>

GA, gestational age; BW, BH, BHC, weight, height and head circumference at birth. Results expressed as mean ± standard deviation and percentage. ns non significant* p < 0.05 ** p < 0.001 for comparison between AGA vs. SGA groups.

pathways, possibly contributing to a defect in growth and metabolic adaptation in this population of FGR babies.

There was several limitations in this prospective study conducted in 73 low birth weight preterm neonates, first prevalence of medically induced prematurity for FGR increases with the gestational age at birth due to obstetrical FGR

management. Second, at day 60, an important number of patients has been lost to follow-up, including all the SGA neonates which had been discharged. Both limitations could have been source of significant bias in our study.

We first described post-natal growth and observed persistence in differences of auxological parameters between SGA and
<figure><img src="image_4.png" /><figcaption>**FIGURE 2** | Evolution of growth parameters during the first 2 months of life. Day 0 (D0): all *n* = 73/AGA *n* = 50 vs. SGA *n* = 23/insulin *n* = 18 vs. no insulin *n* = 55. Day 10 (D10): all *n* = 60/AGA *n* = 42 vs. SGA *n* = 18/insulin *n* = 16 vs. no insulin *n* = 44. Day 30 (D30): all *n* = 39/AGA *n* = 32 vs. SGA *n* = 7/insulin *n* = 13 vs. no insulin *n* = 26. Day 60 (D60): all *n* = 17/AGA *n* = 17 vs. SGA *n* = 0/insulin *n* = 7 vs. no insulin *n* = 10. Results expressed in mean ± standard deviation. \*\*p < 0.01 \*\*\*p < 0.0001.</figcaption></figure>
<table><caption>**TABLE 2** | mean plasma concentration of GH, IGF1 and insulin at day 3, 10 and 30 [mean ± standard deviation (min-max)].</caption><thead><tr><th></th><th></th><th>GH (mIU/L)</th><th>IGF1 (ng/ml)</th><th>Insulin (mIU/L)</th></tr></thead><tbody><tr><td rowspan="6">Day 3</td><td><strong>All (n = 51)</strong></td><td><strong>50 ± 41 (5–208)</strong></td><td><strong>9 ± 8 (1–29)</strong></td><td><strong>27 ± 46 (1–307)</strong></td></tr><tr><td>&lt; 28 weeks GA</td><td>42 ± 37 (11–110)</td><td>5.8 ± 6 (1–23)</td><td>34 ± 35 (2–131)</td></tr><tr><td>AGA (n = 32)</td><td>38 ± 28 (6–110)</td><td>8 ± 8 (2–29)</td><td>25 ± 26 (1–131)</td></tr><tr><td>SGA (n = 19)</td><td>70 ± 51 (5–208)**</td><td>10 ± 7 (1–25)</td><td>31 ± 74 (1–307)</td></tr><tr><td>Insulin (n = 14)</td><td>44 ± 38 (5–110)</td><td>5 ± 7 (1–23)</td><td>56 ± 83 (5–208)</td></tr><tr><td>No insulin (n = 47)</td><td>52 ± 42 (6–208)</td><td>10 ± 8 (1–29)</td><td>18 ± 20 (1–80)</td></tr><tr><td rowspan="6">Day 10</td><td><strong>All (n = 34)</strong></td><td><strong>38 ± 25 (5–148)</strong></td><td><strong>21 ± 12 (1–40)</strong></td><td><strong>16 ± 16 (1–80)</strong></td></tr><tr><td>&lt; 28 weeks GA</td><td>43 ± 44 (5–148)</td><td>11 ± 8 (1–25)</td><td>31 ± 25 (7–80)</td></tr><tr><td>AGA (n = 26)</td><td>38 ± 28 (5–148)</td><td>19 ± 12 (1–40)</td><td>18 ± 19 (1–80)</td></tr><tr><td>SGA (n = 8)</td><td>38 ± 10 (23–52)</td><td>29 ± 10 (13–39)*</td><td>11 ± 8 (1–23)</td></tr><tr><td>Insulin (n = 10)</td><td>39 ± 42 (5–148)</td><td>16 ± 8 (1–25)</td><td>30 ± 23 (12–80)*</td></tr><tr><td>No insulin (n = 24)</td><td>38 ± 16 (12–75)</td><td>24 ± 13 (1–40)</td><td>10 ± 9 (1–36)</td></tr><tr><td rowspan="6">Day 30</td><td><strong>All (n = 25)</strong></td><td><strong>47 ± 29 (14–144)</strong></td><td><strong>26 ± 13 (1–48)</strong></td><td><strong>14 ± 14 (1–61)</strong></td></tr><tr><td>&lt; 28 weeks GA</td><td>48 ± 26 (21–80)</td><td>18 ± 12 (1–48)</td><td>12 ± 6 (1–21)</td></tr><tr><td>AGA (n = 23)</td><td>43 ± 20 (14–82)</td><td>25 ± 13 (1–48)</td><td>15 ± 14 (1–61)</td></tr><tr><td>SGA (n = 2)</td><td>(35–144)</td><td>(37–40)</td><td>(2)</td></tr><tr><td>Insulin (n = 8)</td><td>42 ± 27 (14–80)</td><td>23 ± 15 (13–48)</td><td>13 ± 5 (7–21)</td></tr><tr><td>No insulin (n = 17)</td><td>50 ± 32 (17–144)</td><td>29 ± 11 (13–45)</td><td>15 ± 16 (1–61)</td></tr></tbody></table>

AGA groups during hospitalization. However, the differences were reduced progressively, mainly due to extra-uterine growth retardation (EUGR) in AGA neonates. We also found that preterm babies requiring insulin for idiopathic hyperglycemia, who had a higher birth weight percentile had lower weight and HC at day 60. Two others studies have found similar results: Scheurer et al. described that hyperglycemic preterm neonates were discharged with lower HC and had lower height, weight, and HC at four months post-discharge (26); Ramel and colleagues published that height, weight, and HC of hyperglycemic preterm neonates were lower at 36 months (27). These results are in accordance with our hypothesis of a resistance to the anabolic effect of insulin and concomitantly a poor response on growth of GH/IGF1 axis in this population.

In the second part, we analyzed plasma levels of GH, IGF1 and insulin. It has been reported that random GH values are clinically useful within the first month of life, and that serum IGF1 levels reflect spontaneous 24 h GH secretion (28, 29). GH plasma concentrations were elevated during the first month of life, as previously reported (28). A large proportion of the neonates exhibited spontaneous GH levels superior to 20 mIU/L (usual threshold used to define deficiency during GH stimulation test) while very few exhibited GH levels inferior to 10 mIU/ml. On the contrary, IGF1 plasma concentrations were very low at birth and progressively increased during the first month. They were frequently below the minimum threshold of the assay at birth. Overall, this suggests a resistance to GH action during the first month of life in this population.

At birth, there was no correlation between GH and BW or GA while IGF1 was discretely correlated to BW. However, BW percentile was correlated with GH levels, but not with IGF1 levels. GH and IGF1 plasma levels were also higher in SGA neonates, respectively, at day 3 and 10. GH and IGF1 plasma levels were not

correlated before day 30. This suggests a higher level of resistance to GH and IGF1 in the first days of life in SGA neonates.

There are no precedent studies on GH plasma levels in this population but our results are in concordance with the few studies on IGF1 plasma levels in preterm babies (30). It has also been showed that IGF1 plasma concentration at birth was lower in SGA neonates (31), that mRNA and IGF1 protein were less expressed and translated in the placenta of SGA neonates (32). While IGF1 plasma levels were lower at birth they were found higher at 1 and 3 years in SGA children compared with AGA children (33). In addition, if SGA neonates do not exhibit catch-up growth before 3 years of life, IGF1 plasma levels remain lower at day 30 and 60 (30, 34).

Fetal growth relies on insulin and nutrient intake, and GH does not play a significant role in fetal and neonatal growth. Consistently, children with pan-hypopituitarism are not SGA and have no growth failure in the first months of life but frequently are hypoglycemic with low IGF1 levels (35). Conversely, children with defects in IGF1 signalization are SGA (36), and many polymorphisms in *IGF1* and *IGF1R* genes have been described associated with FGR (37, 38). This dissociation in the role of GH and IGF1 in fetal growth suggests that IGF1 secretion is partially independent of GH during this period. Fetal growth is largely due to insulin and nutrient intake [example of gestational diabetes mellitus (39)] but also to Insulin-like Growth Factor 2 (IGF2). This latter is central in the pathophysiology of Silver-Russel syndrome [SRS, low IGF2 and very SGA neonates (40)]. IGF1, IGF2 and insulin (and their respective receptors) share structural analogy, and their signalizations have cross-linked interactions (41). We suggest that SGA neonates, similarly to SRS children, might have a defect in the IGF system with compensatory increase in GH levels.

<footnote>*p < 0.05 **p < 0.01 for comparison between AGA vs. SGA or insulin vs. no insulin groups.</footnote>
In our study, 22% of the neonates required insulin therapy for idiopathic hyperglycemia (45% among <28 weeks). All were born before 32 weeks and/or with a birth weight <1,500 g, concordant with previous findings (7). There was no correlation between insulin plasma levels and birth weight or gestational age. We observed a great variability in the plasma concentrations of insulin, especially among those who required insulin therapy. This is in accordance with the hypothesis that idiopathic hyperglycemia of the preterm neonate is related to both insulinopenia (due to abnormality in insulin biosynthesis during post-translational stages with pro-insulin accumulation) and insulin resistance (9, 10, 42). Nevertheless, considering that we analyzed neither the impact of nutritional intake nor the correlation with glycaemia during the insulin assay, these results should be taken with caution, even if all the neonates were managed with standardized procedures of enteral and parenteral nutrition according to ESPGHAN guidelines.

SGA neonates displayed a risk to develop metabolic syndrome (5, 23, 25) and SGA children have insulin resistance (43, 44). Some studies even correlate Homeostasis Model Assessment of Insulin Resistance (HOMA) index and higher IGF1 levels during childhood (45). Conversely, the absence of insulin resistance and better insulin secretion is correlated with a better catch-up growth (46, 47). Thus, post-natal growth and insulin sensitivity seem to be associated. Murine models have emphasized the correlation between lack of catch-up growth in SGA rats and GH resistance (14) and the existence of cross-linked interactions between insulin and GH/IGF1 axis pathways (15).

Overall, our results suggest GH and IGF1 resistance in addition to insulin resistance during the first weeks of life in SGA neonates.

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by CNIL n°2051804. Written informed consent from the participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

## AUTHOR CONTRIBUTIONS

EM-S, PB, and DD conceived and designed the study. EM-S, SS-A, YS, VD, and RB provided clinical data. SB-T performed the biochemical assays. EM-S and PB analyzed the data. EM-S drafted the article and SS-A, PB, and DD revised it critically for important intellectual content. All authors contributed to the article and approved the submitted version.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped. 2021.711400/full#supplementary-material

**Supplemental Figure 1** | Correlation between GH/IGF1 plasma concentrations at birth (day 0 to 3) and gestational age (GA), birth weight (BW) and BW Fenton percentile (each point represents a single neonate, n=51).

## REFERENCES

1. Ancel P-Y, Goffinet F, EPIPAGE-2 Writing Group, Kuhn P, Langer B, Matis J, et al. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study. *JAMA Pediatr*. (2015) 169:230–8. doi: 10.1001/jamapediatrics.2014.3351

2. Ego A. [Definitions: small for gestational age and intrauterine growth retardation]. *J Gynecol Obstet Biol Reprod*. (2013) 42:872–94. doi: 10.1016/j.jgyn.2013.09.012/8

3. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD neonatal research network. *Pediatrics*. (2010) 126:443–56. doi: 10.1542/peds.2009-2959

4. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ*. (1989) 298:564–7. doi: 10.1136/bmj.298.6673.564

5. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet Lond Engl*. (1993) 341:938–41. doi: 10.1016/0140-6736(93)91224-A

6. Vaag A, Jensen CB, Poulsen P, Brøns C, Pilgaard K, Grunnet L, et al. Metabolic aspects of insulin resistance in individuals born small for gestational age. *Horm Res*. (2006) 65(Suppl. 3):137–43. doi: 10.1159/000091519

7. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, Ong K, et al. Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. *J Pediatr*. (2010) 157:715–9.e1-3. doi: 10.1016/j.jpeds.2010.04.032

8. Zamir I, Tornevi A, Abrahamsson T, Ahlsson F, Engström E, Hallberg B, et al. Hyperglycemia in extremely preterm infants: insulin treatment, mortality and nutrient intakes. *J Pediatr*. (2018) 200:104–10.e1. doi: 10.1016/j.jpeds.2018.03.049

9. Mitanchez-Mokhtari D, Lahlou N, Kieffer F, Magny J-F, Roger M, Voyer M. Both relative insulin resistance and defective islet beta-cell processing of proinsulin are responsible for transient hyperglycemia in extremely preterm infants. *Pediatrics*. (2004) 113(3 Pt 1):537–41. doi: 10.1542/peds.113.3.537

10. Salis ER, Reith DM, Wheeler BJ, Broadbent RS, Medlicott NJ. Hyperglycaemic preterm neonates exhibit insulin resistance and low insulin production. *BMJ Paediatr Open*. (2017) 1:e000160. doi: 10.1136/bmjpo-2017-000160

11. Gluckman PD, Pinal CS. Regulation of fetal growth by the somatotrophic axis. *J Nutr*. (2003) 133(5 Suppl 2):1741S–6S. doi: 10.1093/jn/133. 5.1741S

12. Benyi E, Sävendahl L. The physiology of childhood growth: hormonal regulation. *Horm Res Paediatr*. (2017) 88:6–14. doi: 10.1159/000471876

13. Alsat E, Guibourdenche J, Couturier A, Evain-Brion D. Physiological role of human placental growth hormone. *Mol Cell Endocrinol*. (1998) 140:121–7. doi: 10.1016/S0303-7207(98)00040-9

14. Huang Y, Du M, Zhuang S, Shen Z, Li Y. Impaired growth hormone receptor signaling during non-catch-up growth in rats born small for gestational age. *Horm Res Paediatr*. (2010) 74:106–13. doi: 10.1159/000313374

15. Deng H-Z, Deng H, Cen C-Q, Chen K-Y, Du M-L. Post-receptor crosstalk between growth hormone and insulin signal in rats born small for gestational age with catch-up growth. *PLoS ONE*. (2014) 9:e100459. doi: 10.1371/journal.pone.0100459

16. Monier I, Ancel P-Y, Ego A, Jarreau P-H, Lebeaux C, Kaminski M, et al. Fetal and neonatal outcomes of preterm infants born before 32 weeks of gestation according to antenatal vs. postnatal assessments of restricted growth. *Am J Obstet Gynecol*. (2017) 216:516.e1–516.e10. doi: 10.1016/j.ajog.2017. 02.001

17. Hales CN, Barker DJ. The thrifty phenotype hypothesis. *Br Med Bull*. (2001) 60:5–20. doi: 10.1093/bmb/60.1.5
18. Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R, Parenteral Nutrition Guidelines Working Group, et al. 1. Guidelines on paediatric parenteral nutrition of the European society of paediatric gastroenterology, hepatology and nutrition (ESPGHAN) and the European society for clinical nutrition and metabolism (ESPEN), supported by the European society of paediatric research (ESPR). *J Pediatr Gastroenterol Nutr.* (2005) 41(Suppl. 2):S1–87. doi: 10.1097/01.mpg.0000181841.07090.f4

19. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. *BMC Pediatr.* (2003) 3:13. doi: 10.1186/1471-2431-3-13

20. Clark RH, Thomas P, Peabody J. Extrauterine growth restriction remains a serious problem in prematurely born neonates. *Pediatrics*. (2003) 111:986–90. doi: 10.1542/peds.111.5.986

21. Picon L. Effect of insulin on growth and biochemical composition of the rat fetus. *Endocrinology*. (1967) 81:1419–21. doi: 10.1210/endo-81-6-1419

22. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. *Cell*. (1993) 75:73–82. doi: 10.1016/S0092-8674(05)080085-6

23. De Jong M, Cranendonk A, van Weissenbruch MM. Components of the metabolic syndrome in early childhood in very-low-birth-weight infants and term small and appropriate for gestational age infants. *Pediatr Res.* (2015) 78:457–61. doi: 10.1038/pr.2015.118

24. Kistner A, Rakow A, Legnevall L, Marchini G, Brismar K, Hall K, et al. Differences in insulin resistance markers between children born small for gestational age or born preterm appropriate for gestational age. *Acta Paediatr Oslo Nor 1992*. (2012) 101:1217–24. doi: 10.1111/apa.12005

25. Milovanovic I, Njujeyan F, Deghmoun S, Chevenne D, Levy-Marchal C, Beltrand J. SGA children with moderate catch-up growth are showing the impaired insulin secretion at the age of 4. *PLoS ONE*. (2014) e100337. doi: 10.1371/journal.pone.0100337

26. Scheurer JM, Gray HL, Demerath EW, Rao R, Ramel SE. Diminished growth and lower adiposity in hyperglycemic very low birth weight neonates at 4 months corrected age. *J Perinatol Off J Calif Perinat Assoc*. (2016) 36:145–50. doi: 10.1038/jp.2015.154

27. Ramel SE, Long JD, Gray H, Durrwachter-Erno K, Demerath EW, Rao R. Neonatal hyperglycemia and diminished long-term growth in very low birth weight preterm infants. *J Perinatol Off J Calif Perinat Assoc*. (2013) 33:882–6. doi: 10.1038/jp.2013.77

28. Hawkes CP, Grimberg A. Measuring growth hormone and insulin-like growth factor-i in infants: what is normal? *Pediatr Endocrinol Rev PER*. (2013) 11:126–46.

29. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. *J Clin Endocrinol Metab*. (1993) 76:1610–6. doi: 10.1210/jcem.76.6.7684744

30. Ohkawa N, Shoji H, Kitamura T, Suganuma H, Yoshikawa N, Suzuki M, et al. IGF-I, leptin and active ghrelin levels in very low birth weight infants during the first 8 weeks of life. *Acta Paediatr Oslo Nor 1992*. (2010) 99:37–41. doi: 10.1111/j.1651-2227.2009.01516.x

31. Martos-Moreno GA, Barrios V, Sáenz de Pipaón M, Pozo J, Dorronsoro I, Martínez-Biarge M, et al. Influence of prematurity and growth restriction on the adipokine profile, IGF1, and ghrelin levels in cord blood: relationship with glucose metabolism. *Eur J Endocrinol*. (2009) 161:381–9. doi: 10.1530/EJE-09-0193

32. Nawathe AR, Christian M, Kim SH, Johnson M, Savvidou MD, Terzidou V. Insulin-like growth factor axis in pregnancies affected by fetal growth disorders. *Clin Epigenetics*. (2016) 8:11. doi: 10.1186/s13148-016-0178-5

33. Iñiguez G, Ong K, Bazaes R, Avila A, Salazar T, Dunger D, et al. Longitudinal changes in insulin-like growth factor-I, insulin sensitivity, and secretion from birth to age three years in small-for-gestational-age children. *J Clin Endocrinol Metab*. (2006) 91:4645–9. doi: 10.1210/jc.2006-0844

34. Ohkawa N, Shoji H, Ikeda N, Suganuma H, Shimizu T. Relationship between insulin-like growth factor 1, leptin and ghrelin levels and catch-up growth in small for gestational age infants of 27-31 weeks during neonatal intensive care unit admission. *J Paediatr Child Health*. (2017) 53:62–7. doi: 10.1111/jpc.13307

35. Castinetti F, Reynaud R, Quentien M-H, Jullien N, Marquant E, Rochette C, et al. Combined pituitary hormone deficiency: current and future status. *J Endocrinol Invest*. (2015) 38:1–12. doi: 10.1007/s40618-014-0141-2

36. Klammt J, Pfäffle R, Werner H, Kiess W. IGF signaling defects as causes of growth failure and IUGR. *Trends Endocrinol Metab TEM*. (2008) 19:197–205. doi: 10.1016/j.tem.2008.03.003

37. Ester WA, Hokken-Koelega ACS. Polymorphisms in the IGF1 and IGF1R genes and children born small for gestational age: results of large population studies. *Best Pract Res Clin Endocrinol Metab*. (2008) 22:415–31. doi: 10.1016/j.beem.2008.03.001

38. Landmann E, Kollerits B, Kreuder JG, Blum WF, Kronenberg F, Rudloff S. Influence of polymorphisms in genes encoding for insulin-like growth factor (IGF)-I, insulin, and IGF-binding protein (IGFBP)-3 on IGF-I, IGF-II, and IGFBP-3 levels in umbilical cord plasma. *Horm Res Paediatr*. (2012) 77:341–50. doi: 10.1159/000338783

39. Billionnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. *Diabetologia*. (2017) 60:636–44. doi: 10.1007/s00125-017-4206-6

40. Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J, et al. Diagnosis and management of silver-russell syndrome: first international consensus statement. *Nat Rev Endocrinol*. (2017) 13:105–24. doi: 10.1038/nrendo.2016.138

41. Rotwein P. Large-scale analysis of variation in the insulin-like growth factor family in humans reveals rare disease links and common polymorphisms. *J Biol Chem*. (2017) 292:19608. doi: 10.1074/jbc.M117.783639

42. Salis ER, Reith DM, Wheeler BJ, Broadbent RS, Medicott NJ. Insulin resistance, glucagon-like peptide-1 and factors influencing glucose homeostasis in neonates. *Arch Dis Child Fetal Neonatal Ed*. (2017) 102:F162–6. doi: 10.1136/archdischild-2015-309174

43. Evagelidou EN, Giapros VI, Challa AS, Kiortsis DN, Tsatsoulis AA, Andronikou SK. Serum adiponectin levels, insulin resistance, and lipid profile in children born small for gestational age are affected by the severity of growth retardation at birth. *Eur J Endocrinol. fevr*. (2007) 156:271–7. doi: 10.1530/eje.1.02337

44. Hernandez MI, Rossel K, Peña V, Garcia M, Cavada G, Avila A, et al. Patterns of infancy growth and metabolic hormonal profile are different in very-low-birth-weight preterm infants born small for gestational age compared to those born appropriate for gestational age. *Horm Res Paediatr*. (2018) 89:233–45. doi: 10.1159/000487994

45. Tenhola S, Halonen P, Jääskeläinen J, Voutilainen R. Serum markers of GH and insulin action in 12-year-old children born small for gestational age. *Eur J Endocrinol*. (2005) 152:335–40. doi: 10.1530/eje.1.01869

46. Soto N, Bazaes RA, Peña V, Salazar T, Avila A, Iñiguez G, et al. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. *J Clin Endocrinol Metab*. (2003) 88:3645–50. doi: 10.1210/jc.2002-030031

47. Sato R, Maekawa M, Genma R, Shirai K, Ohki S, Morita H, et al. Final height and cardiometabolic outcomes in young adults with very low birth weight (<1500 g). *PLoS ONE*. (2014) e9:e112286. doi: 10.1371/journal.pone.0112286

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Motte-Signoret, Shankar-Aguilera, Brailly-Tabard, Soreze, Dell Orto, Ben Ammar, De Luca and Boileau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.